Category: Baxter International
Baxter reports 2nd-quarter sales growth of more than 16% and beats earnings expectations, but narrows its full-year earnings guidance.
JenaValve taps ex-AtriCure chief David Drachman to be its new CEO.
, Bioject Medical Technologies Inc.
, Echo Therapeutics Inc.
, Hill-Rom Holdings Inc.
, Integrity Applications
, U.S. Veterans Affairs Dept. (VA)
, GI Dynamics
Here's a look at some of the top legal news stories for medical device companies this week: J&J's Conor MedSystems can't slip $100M Biotronik lawsuit; Supreme Court declines review of Baxter/Fresenius patent row; Medtronic, Edwards ink $750M heart valve settlement; Pa. Supreme Court to review $28M Zimmer verdict; Laid off Italian workers sue Haemonetics.
Fresenius escapes for good a $24 million patent infringement loss to dialysis rival Baxter International after the U.S. Supreme court declines to review the case.
Improvements Include Increased Drug Library Capacity and Device Tracking Services.
Illinois-based Baxter lands FDA clearance for its next-generation Sigma Spectrum infusion pump, which includes a "Master Drug Library" of facility-specific drugs and dosing parameters.
Baxter (NYSE:BAX) this week touted FDA clearance for its next-generation Sigma Spectrum infusion pump with safety software that allows hospitals to set drug delivery parameters to minimize dosing errors.
Baxter's infusion pump recall is associated with 9 severe adverse events and more than 3,500 complaints, getting the FDA's attention and highest-risk warning label.
Medtech maker Baxter (NYSE:BAX) got the FDA's highest-risk warning after recalling a series of infusion pumps due to a software issue that could lead the devices to malfunction.